Our study showed that both interleukin-1 beta (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra) levels in CSF were significantly lower in patients with newly diagnosed relapsing-remitting multiple sclerosis (RRMS) than in healthy controls. Here, IL1B is linked to relapsing-remitting multiple sclerosis.